Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | F11 | P03951 | 2/20 | 0.53 |
| ▸ | KLK1 | P06870 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | PRKX | P51817 | 1/20 | 0.52 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.52 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004054 | 1.00 | ROCK2 (0.56) | ROCK2ROCK1RAB9AKDM4EGAA | |
| Hydrochloric Acid SCHEMBL3010159 | 0.90 | ROCK2 (0.67) | ROCK2ROCK1RAB9AMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL3010160 | 0.90 | ROCK2 (0.67) | ROCK2ROCK1RAB9AMAPTNPC1 | |
| SCHEMBL3009803 | 0.81 | ROCK2 (0.54) | ROCK2ROCK1RAB9AMAPTNPC1 | |
| SCHEMBL3009807 | 0.81 | ROCK2 (0.54) | ROCK2ROCK1RAB9AMAPTNPC1 | |
| SCHEMBL1614525 | 0.80 | BACE1 (0.54) | ROCK2ROCK1RAB9AKDM4EGAA | |
| SCHEMBL5145729 | 0.80 | BACE1 (0.54) | ROCK2ROCK1RAB9AKDM4EGAA | |
| SCHEMBL16599266 | 0.79 | SYK (0.49) | ROCK2ROCK1RAB9AKDM4EGAA | |
| SCHEMBL2995006 | 0.79 | SGK1 (0.51) | ROCK2ROCK1F11AKT1 | |
| SCHEMBL2994999 | 0.79 | SGK1 (0.51) | ROCK2ROCK1F11AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049390-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | disclosed |
| EP-3049394-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | disclosed |
| EP-3049408-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | disclosed |
| EP-3049404-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | disclosed |
| EP-3049403-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015044163-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015044167-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015044165-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015044169-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015044172-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | ROCK2 3532/4885ROCK1 2739/4885RAB9A 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.